Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. for $19.00 per share in cash, representing an 82% premium to Intercept’s closing price on September 25, 2023. The deal is structured as a cash tender offer followed by a second-step merger and is expected to close by the end of 2023, pending conditions including a minimum tender and regulatory requirements.